RT Journal Article
SR Electronic
T1 Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.30.20160069
DO 10.1101/2020.07.30.20160069
A1 Dowdell, Alexa K
A1 Matlock, Kevin
A1 Robinson, Fred L.
A1 Weerasinghe, Roshanthi
A1 Rattray, Rogan
A1 Pukay, Marina
A1 Lathara, Melvin
A1 Harlan, Anastacia
A1 Ward, Thomas R.
A1 Campbell, Mary
A1 Urba, Walter
A1 Srinivasa, Ganapati
A1 Bifulco, Carlo B.
A1 Piening, Brian D.
YR 2020
UL http://medrxiv.org/content/early/2020/08/04/2020.07.30.20160069.abstract
AB The first reported case of COVID-19 in the State of Oregon occurred in late February 2020, with subsequent outbreaks occurring in the populous Portland metro area but also with significant outbreaks in less-populous and rural areas. Here we report viral sequences from 188 patients across the hospitals and associated clinics in the Providence Health System in the State of Oregon dating back to the early days of the outbreak. We show a significant shift in dominant clade lineages over time in Oregon, with the rapid emergence and dominance of Spike D614G-positive variants. We also highlight significant diversity in SARS-CoV-2 sequences in Oregon, including a large number of rare mutations, indicative that these genomes could be utilized for outbreak tracing. Lastly, we show that SARS-CoV-2 genomic information may offer additional utility in combination with clinical covariates in the prediction of acute disease phenotypes.Competing Interest StatementKM, ML and GS are employees of and hold a vested interest in Omics Data Automation, Inc.Funding StatementThis work was supported by a grant from Providence Foundations of Oregon. Omics Data Automation employees (KM, ML and GS) were supported by a grant from the National Science Foundation under award #1721343.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Providence St Joseph Health Institutional Review Board reviewed and approved this study (IRB protocol number 2020000127).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll SARS-CoV-2 sequences generated for this manuscript are publicly available through GISAID.org (under originating laboratory Providence St. Joseph Health Molecular Genomics Laboratory or by author filter for Dowdell et al.). Deidentified clinical data are available upon request. http://www.gisaid.org